Expanding on this, Schott et al. found that PD-L1 positive CTCs are present on both earlier and metastatic disease stages [186] and reported that one patient showed a reduction in PD-L1+ CTCs, with successful nivolumab and ipilimumab treatment. Here, CD274 is linked to metastatic neoplasm.